Clinical Trial Update: An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study of CHF 718 met its completion with results posted, investigating efficacy and safety in asthmatic subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• CHF 718

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2021-12-14